Neuropeptide Y potentiates the pressor response evoked by carbachol administration into the posterior hypothalamic nucleus of conscious rat

Brain Research

Volumn 949, Issue 1-2, 2002, Pages 79-87

  Martin, John R ^a  

^a A T STILL UNIVERSITY   (United States)

Author keywords

Blood pressure; Cholinergic; NPY; Posterior hypothalamus; PYX 2; Y receptor

Indexed keywords

CARBACHOL; NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; PYX 2; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONSCIOUSNESS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENCY; DRUG POTENTIATION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; POSTERIOR HYPOTHALAMUS; PRESSOR RESPONSE; PRIORITY JOURNAL; RAT;

ANIMALS; BLOOD PRESSURE; CARBACHOL; CHOLINERGIC AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART RATE; HYPOTHALAMUS, POSTERIOR; MALE; MICROINJECTIONS; NEUROPEPTIDE Y; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 0037072544     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(02)02967-0     Document Type: Article

References (42)

1. Aakerlund L., Gether U., Fuhlendorff J., Schwartz T.W., Thastrup O. Y1 receptors for neuropeptide Y are coupled to mobilization of intracellular calcium and inhibition of adenylate cyclase. FEBS Lett. 260:1990;73-78.
2. Abrahamson E.E., Moore R.Y. The posterior hypothalamic area: chemoarchitecture and afferent connections. Brain Res. 889:2001;1-22.
3. Aguirre J.A., Fuxe K., Hedlund P., Narvaez J.A., Cintra A., Rosen L., Agnati L.F. Neuropeptide Y/angiotensin II interactions in central cardiovascular regulation of the rat. Brain Res. 566:1991;61-69.
4. Allen Y.S., Adrian T.E., Allen J.M., Tatemoto K., Crow T.J., Bloom S.R., Polak J.M. Neuropeptide Y distribution in the rat brain. Science, Washington, D.C. 221:1983;877-879.
5. Ault D.T., Werling L.L. Differential modulation of NMDA-stimulated [3H]dopamine release from rat striatum by neuropeptide Y and sigma receptor ligands. Brain Res. 760:1997;210-217.
6. Ault D.T., Radeff J.M., Werling L.L. Modulation of [3H]dopamine release from rat nucleus accumbens by neuropeptide Y may involve a sigma1-like receptor. J. Pharmacol. Exptl. Therap. 284:1988;553-560.
7. Buccafusco J.J., Brezenoff H.E. Pharmacological study of a cholinergic mechanism within the rat posterior hypothalamic nucleus which mediates a hypertensive response. Brain Res. 165:1979;295-310.
8. Chronwall B.M., DiMaggio D.A., Massarir V.J., Pickel V.M., Ruggierio D.A., O'Donohue T.L. The anatomy of neuropeptide-Y-containing neurons in rat brain. Neuroscience. 15:1985;1159-1181.
9. Doods H.N., Wienen W., Entzeroth M., Rudolf K., Eberlein W., Engel W., Wieland H.A. Pharmacological characterization of the selective nonpeptide neuropeptide Y Y1 receptor antagonist BIBP 3226. J. Pharmacol. Exp. Ther. 275:1995;136-142.
10. Fallgren B., Anlock P., Edvinsson L. Neuropeptide Y potentiates noradrenaline-evoked vasoconstriction by an intracellular calcium-dependent mechanism. J. Auton. Nerv. Syst. 44:1993;151-159.
11. Feth F., Rascher W., Michel M.C. Neuropeptide Y (NPY) receptors in HEL cells: comparison of binding and functional parameters for full and partial agonists and a nonpeptide antagonist. Br. J. Pharmacol. 105:1992;71-76.
12. Fohrman E.B., de Erausquin G., Costa E., Wojcik W.J. Muscarinic m3 receptors and dynamics of intracellular Ca2+ cerebellar granule nerves. Eur. J. Pharmacol. 245:1993;263-271.
13. Golombek D.A., Biello S.M., Rendon R.A., Harrington M.E. Neuropeptide Y phase shifts the circadian clock in vitro via a Y2 receptor. Neuroreport. 7:1996;1315-1319.
14. Gribkoff V.K., Pieschl R.L., Wisialowski T.A., van den Pol A.N., Yocca F.D. Phase shifting of circadian rhythms and depression of neuronal activity in the rat suprachiasmatic nucleus by neuropeptide Y: mediation by different receptor subtypes. J. Neurosci. 18:1998;3014-3022.
15. Hastings J.A., Pavia J.M., Morris M.J. Neuropeptide Y and [Leu31, Pro34]neuropeptide Y potentiate potassium-induced noradrenaline release in the paraventricular nucleus of the aged rat. Brain Res. 750:1997;301-304.
16. Lee C.C., Miller R.J. Is there really an NPY Y3 receptor? Regul. Pept. 75-76:1998;71-78.
17. Martin J.R. Pressor response to posterior hypothalamic administration of carbachol is mediated by muscarinic M3 receptor. Eur. J. Pharmacol. 215:1992;83-91.
18. Martin J.R. Mechanisms of the cardiovascular response to posterior hypothalamic nucleus administration of carbachol. J. Cardiovasc. Pharmacol. 27:1996;891-990.
19. Martin J.R. Evidence of systemic neuropeptide Y release after carbachol administration into the posterior hypothalamic nucleus. J. Cardiovasc. Pharmacol. 28:1996;447-457.
20. Martin J.R., Beinfeld M.C., Westfall T.C. Blood pressure increases after injection of neuropeptide Y into posterior hypothalamic nucleus. Am. J. Physiol. 254:1988;H879-H888.
21. Martin J.R., Knuepfer M.M., Beinfeld M.C., Westfall T.C. Mechanism of pressor response to posterior hypothalamic injection of neuropeptide Y. Am J. Physiol. 257:1989;H791-H798.
22. Martin J.R., Knuepfer M.M., Westfall T.C. Hemodynamic effects of posterior hypothalamic injection of neuropeptide Y in awake rats. Am. J. Physiol. 261:1991;H814-H824.
23. Martire M., Fuxe K., Pistritto G., Preziosi P., Agnati L.F. Reduced inhibitory effects of clonidine and neuropeptide Y on 3H-noradrenaline release from synaptosomes of the medulla oblongata of the spontaneously hypertensive rat. J. Neural Trans. 67:1989;113-124.
24. Michel M.C., Beck-Sickinger A., Cox H., Doods H.N., Herzog H., Larhammer D., Quirion R., Schwartz T., Westfall T. XVI. International union of pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol. Rev. 50:1998;143-150.
25. Michel M.C., Schlicker E., Fink K., Boubik J.H., Gothert M., Willette R.N., Daly R.N., Hieble J.P., Rivier J.E., Motulsky H.I. Distinction of NPY receptors in vitro and in vivo. I. NPY(18-36) discriminates receptor subtypes in vitro. Am. J. Physiol. 259:1990;E131-E139.
26. Nahorski S.R., Tobin A.B., Willars G.B. Muscarinic M3 receptor coupling and regulation. Life Sci. 60:1997;1039-1045.
27. Obrietan K., van den Pol A.N. Neuropeptide Y depresses GABA-mediated calcium transients in developing suprachiasmatic nucleus neurons: a novel form of calcium long-term depression. J. Neurosci. 16:1996;3521-3533.
28. Palkovits M., Jacobowitz D.M. Topographic atlas of catecholamines and acetylcholinesterase-containing neurons in the rat brain. II. Hindbrain (mesencephalon, rhombencephalon). J. Comp. Neurol. 157:1974;29-42.
29. Pavia J.M., Hastings J.A., Morris M.J. Neuropeptide Y potentiation of potassium-induced noradrenaline release in the hypothalamic paraventricular nucleus of the rat in vivo. Brain Res. 690:1995;108-111.
30. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1982;Academic Press, New York.
31. Ruggiero D.A., Giuliano R., Anwar M., Stornetta R., Reis D.J. Anatomical substrates of cholinergic-autonomic regulation in the rat. J. Comp. Neurol. 292:1990;1-53.
32. Rudolf K., Eberlein W., Engel W., Wieland H.A., Willim K.D., Entzeroth M., Wienen W., Beck-Sickinger A.G., Doods H.N. The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP3226. Eur. J. Pharmacol. 271:1994;R11-R13.
33. Satoh K., Armstrong D.M., Fibiger H.C. A comparison of the distribution of central cholinergic neurons as demonstrated by acetylcholinesterase pharmacohistochemistry and choline acetyltransferase immunohistochemistry. Brain Res. Bull. 11:1983;693-720.
34. Tallarida R.J., Murray R.B. Manual of Pharmacologic Calculations. 1981;Springer-Verlag, New York.
35. Tatemoto L., Carlquist M., Mutt V. Neuropeptide Y - a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature, London. 296:1982;659-660.
36. Tatemoto K., Mann M.J., Shimuzi M. Synthesis of receptor antagonists of neuropeptide Y. Proc. Natl. Acad. Sci. USA. 89:1992;1174-1178.
37. Tseng C.J., Ger L.P., Tung C.S. Interrelation between alpha2-adrenoceptor system and neuropeptide Y in rat nucleus tractus solitarri. Proc. Natl. Sci. Counc. Repub. China [B]. 15:1991;86-91.
38. Tsuda K., Tsuda S., Nishio I., Goldstein M., Masuyama Y. Modulation of [3H]dopamine release by neuropeptide Y in rat striatal slices. Eur. J. Pharmacol. 321:1997;5-11.
39. Uchimura H., Saito M., Hirans M. Regional distribution of choline acetyltransferase in hypothalamus of the rat. Brain Res. 91:1975;161-164.
40. van den Pol A.N., Obrietan K., Chen G., Belousov A.B. Neuropeptide Y-mediated long-term depression of excitatory activity in suprachiasmatic nucleus neurons. J. Neurosci. 16:1996;5883-5895.
41. Westlind-Danielson A., Andell S., Abend J., Bartfai T. Neuropeptide Y and peptide YY inhibit adenylate cyclase activity in the rat striatum. Acta Physiol. Scand. 132:1988;425-430.
42. Wieland H.A., Willim K.D., Entzeroth M., Wienen W., Rudolf K., Eberlein W., Engel W., Doods H.N. Subtype selectivity and antagonistic profile of the nonpeptide Y1 receptor antagonist BIBP 3226. J. Pharmacol. Exp. Ther. 275:1995;143-149.